ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+59.32%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$180M
AUM Growth
+$180M
(+7.2%)
Cap. Flow
-$77.8M
Cap. Flow
% of AUM
-43.26%
Top 10 Holdings %
Top 10 Hldgs %
65.55%
Holding
34
New
12
Increased
4
Reduced
5
Closed
12
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$15.3M |
| 2 |
CG Oncology
CGON
|
$14.1M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$11.9M |
| 4 |
MindMed
MNMD
|
$9.41M |
| 5 |
Kura Oncology
KURA
|
$7.79M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$98.9M |
| 2 |
argenx
ARGX
|
$13.3M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$11.6M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.1M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$8.98M |
Sector Composition
| 1 | Healthcare | 98.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $15.3M | 8.49% | +160,950 | New | +$15.3M |
|
2
Soleno Therapeutics
SLNO
$3.6B
| $14.4M | 8.01% | 336,486 +26,536 | +9% | +$1.14M |
|
|
3
CG Oncology
CGON
$2.04B
| $14.1M | 7.82% | +320,378 | New | +$14.1M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $13.3M | 7.4% | 309,369 +67,408 | +28% | +$2.9M |
|
|
VRNA
5
Verona Pharma
VRNA
$9.16B
| $11.9M | 6.59% | +736,738 | New | +$11.9M |
|
6
Merus
MRUS
$4.98B
| $11.5M | 6.41% | 255,928 -18,995 | -7% | -$855K |
|
7
Praxis Precision Medicines
PRAX
$958M
| $9.73M | 5.41% | 159,486 +89,062 | +126% | +$5.43M |
|
|
8
MindMed
MNMD
$676M
| $9.41M | 5.23% | +1,001,452 | New | +$9.41M |
|
|
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.43B
| $9.24M | 5.14% | 547,036 +200,000 | +58% | +$3.38M |
|
10
Geron
GERN
$893M
| $9.11M | 5.06% | 2,760,497 -211,142 | -7% | -$697K |
|
|
11
Jasper Therapeutics
JSPR
$45.5M
| $8.51M | 4.73% | 289,943 -3,369,312 | -92% | -$98.9M |
|
|
12
Kura Oncology
KURA
$686M
| $7.79M | 4.33% | +365,044 | New | +$7.79M |
|
13
Insmed
INSM
$28.8B
| $6.78M | 3.77% | +250,000 | New | +$6.78M |
|
14
Dianthus Therapeutics
DNTH
$759M
| $6.51M | 3.62% | +216,968 | New | +$6.51M |
|
15
Olema Pharmaceuticals
OLMA
$375M
| $6.33M | 3.52% | 559,035 -100,000 | -15% | -$1.13M |
|
16
Lyra Therapeutics
LYRA
$11.5M
| $6.24M | 3.47% | +1,003,741 | New | +$6.24M |
|
|
LBPH
17
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.84M | 3.25% | +270,559 | New | +$5.84M |
|
18
RAPT Therapeutics
RAPT
$188M
| $3.77M | 2.1% | +420,000 | New | +$3.77M |
|
19
Mersana Therapeutics
MRSN
$36.5M
| $3.59M | 2% | +801,437 | New | +$3.59M |
|
|
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.57M | 1.98% | +394,773 | New | +$3.57M |
|
21
ProMIS Neurosciences
PMN
$28M
| $2.02M | 1.13% | 1,059,582 -7,092 | -0.7% | -$13.5K |
|
22
Context Therapeutics
CNTX
$75.4M
| $1M | 0.56% | 725,951 | – | – |
|
23
Amylyx Pharmaceuticals
AMLX
$836M
| – | – | -275,773 | Closed | -$4.06M |
|
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | -150,000 | Closed | -$8.98M |
|
|
25
argenx
ARGX
$43.6B
| – | – | -35,000 | Closed | -$13.3M |
|